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Summary
The PAX6 gene is involved in ocular morphogenesis,
and PAX6 mutations have been detected in various types
of ocular anomalies, including aniridia, Peters anomaly,
corneal dystrophy, congenital cataract, and foveal hy-
poplasia. The gene encodes a transcriptional regulator
that recognizes target genes through its paired-type
DNA-binding domain. The paired domain is composed
of two distinct DNA-binding subdomains, the N-ter-
minal subdomain (NTS) and the C-terminal subdomain
(CTS), which bind respective consensus DNA sequences.
The human PAX6 gene produces two alternative splice
isoforms that have the distinct structure of the paired
domain. The insertion, into the NTS, of 14 additional
amino acids encoded by exon 5a abolishes the DNA-
binding activity of the NTS and unmasks the DNA-
binding ability of the CTS. Thus, exon 5a appears to
function as a molecular switch that specifies target genes.
We ascertained a novel missense mutation in four ped-
igrees with Peters anomaly, congenital cataract, Axen-
feldt anomaly, and/or foveal hypoplasia, which, to our
knowledge, is the first mutation identified in the splice-
variant region. A TrA transition at the 20th nucleotide
position of exon 5a results in a ValrAsp (GTCrGAC)
substitution at the 7th codon of the alternative splice
region. Functional analyses demonstrated that the V54D
mutation slightly increased NTS binding and decreased
CTS transactivation activity to almost half.
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Introduction
The PAX6 gene, which encodes a transcription regulator
that recognizes target genes through DNA binding of its
paired domain, is involved in ocular morphogenesis
(Treisman et al. 1991; Czerny et al. 1993; Gehring
1996). The gene was isolated, by positional cloning, as
a candidate gene for aniridia (Ton et al. 1991), and nu-
merous mutations have been detected in patients with
aniridia. These mutations are summarized in The Hu-
man PAX6 Mutation Database. Since most of these mu-
tations result in premature translational termination on
one of the alleles, haploinsufficiency of the gene has been
suggested to cause the aniridia phenotype (Fisher and
Scambler 1994; Martha et al. 1994). In contrast, few
missense mutations have been detected to date. Six mu-
tations occur in the paired domain, one in the homeo-
domain, one in the linkage portion between the paired
domain and the homeodomain, and one in the proline-
serine-threonine transactivation domain. Each of these
mutations generates a distinctive phenotype including
aniridia; anterior-segment dysgenesis, which includes Pe-
ters anomaly and corneal dystrophy; and foveal hypo-
plasia (Hanson et al. 1994; Martha et al. 1994; Mir-
zayans et al. 1995; Azuma et al. 1996, 1998a, 1998b;
Tang et al. 1997). The expression pattern of the PAX6
gene also indicates multiple functions of the gene. The
gene is expressed in the developing CNS, as well as in
ocular tissues—including tissues of the corneal epithe-
lium, lens, and retina—that are derived from the ecto-
derm and neuroectoderm (Walther and Gruss 1991).
Thus, PAX6 mutations, especially missense mutations,
may cause numerous types of ocular anomalies, and the
phenotype-genotype correlation must be carefully ex-
amined to elucidate the function of PAX6.
The PAX6 paired domain comprises two structurally
distinct subdomains, the N-terminal subdomain (NTS)
and the C-terminal subdomain (CTS), which bind re-
spective consensus sequences (Epstein et al. 1994a,
1994b). The NTS region is well conserved among mem-
bers of the PAX family of genes, whereas the CTS region
is variable. Initial studies have shown that the NTS plays
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a primary role in DNA binding (Xu et al. 1995). So far,
most missense mutations detected in the PAX family of
genes occur in the NTS, where DNA-binding ability may
be altered (Balling et al. 1988; Baldwin et al. 1992; Tas-
sabehji et al. 1992, 1993; Vogan et al. 1993). However,
recent evidence strongly suggests that the CTS also has
a distinct DNA-binding ability (Epstein et al. 1994a,
1994b). Three missense mutations recently identified in
the CTS also suggest an essential role for the CTS in the
formation of the eye (Chisholm et al. 1995; Azuma et
al. 1996; Tang et al. 1997).
The PAX6 gene produces two isoforms by alternative
splicing with or without exon 5a, and a variant form of
exon 5a has 14 additional amino acid residues inserted
into the NTS of the paired domain. Interestingly, the
insertion not only abolishes NTS function but also en-
hances transactivation activity via the CTS (Epstein et
al. 1994b; Yamaguchi et al. 1997). In contrast, in a case
of isolated foveal hypoplasia, a missense mutation de-
tected in the CTS (Azuma et al. 1996) abolished CTS
function and caused hyperactivation of NTS transcrip-
tion activity. On the basis of these lines of evidence, it
has been proposed that the two subdomains negatively
regulate each other (Yamaguchi et al. 1997). Exon 5a
thus appears to function as a molecular switch that se-
lects and specifies target genes (Epstein et al. 1994b;
Yamaguchi et al. 1997). In the present study, we describe
both a novel missense mutation in the splice-variant re-
gion and the DNA-binding activity of the mutated form.
Material and Methods
DNA Samples
The present study was conducted in accordance with
the World Medical Association Declaration of Helsinki.
Our examination of human subjects was conducted ac-
cording to the program approved by the National Chil-
dren’s Hospital Experimental Review Board and was
deemed exempt from human-subject regulations. We an-
alyzed PAX6 mutations in 55 Japanese pedigrees with
ocular anterior-segment anomalies, including Peters
anomaly and Axenfeldt anomaly; 55 pedigrees with an-
iridia; 70 pedigrees with congenital cataract; 25 pedi-
grees with isolated foveal hypoplasia; and 140 pedigrees
with optic-nerve anomaly. After informed consent was
obtained from all patients, samples of blood from pe-
ripheral veins were collected into lithium-heparin tubes.
Unaffected individuals who were immediate family
members were also examined. Genomic DNA from iso-
lated leukocytes was prepared by means of a standard
phenol/chloroform procedure. DNA samples from nor-
mal controls were prepared as described elsewhere (Ta-
dokoro et al. 1993).
PCR-SSCP Assay and Sequencing
PCR primers used for the amplification of 14 exons
of PAX6 were synthesized according to the sequence
reported by Glaser et al. (1992), by use of a DNA/RNA
synthesizer (model 392; Applied Biosystems). The PCR
conditions that we used (Tadokoro et al. 1993) were
adjusted so that (1) the annealing temperature was 55oC
for exons 5a and 13 and 60oC for the remainder of the
exons, and (2) the Mg concentrations were 1.5 mM.
SSCP analyses were done after the samples were radio-
labeled with a[32P]-dATP, in the PCR reaction, by use
of conventional-size 5% polyacrylamide gels under at
least three different conditions for concentrations of
glycerol and running buffer and running temperature.
Nucleotide sequences were determined, either immedi-
ately or directly after cloning on pUC18, by use of a
Sequenase Version 2 kit (Amersham) with PCR primers
or universal primers in pUC18. Each sequence variation
was confirmed in at least six independent clones.
PAX6 Expression Plasmids
Under the control of the cytomegalovirus enhancer
and the chicken b-actin promoter, bacterial expression
plasmids (pGEX-PrD WT and pGEX-PrD5a WT) have
been used to produce a portion of the PAX6 paired do-
main, with or without exon 5a, and mammalian ex-
pression plasmids (pCMV-PAX6 WT and pCMV-PAX6-
5a WT) have been used to produce the entire PAX6
coding region, with or without exon 5a (Yamaguchi et
al. 1997). The V54D mutation (GTCrGAC) was intro-
duced into a cDNA construct with exon 5a by use of
PCR that incorporated a reverse primer, 5′-TTTCTC-
GAGTTACTGTAATCTTGGCCAGTATTG-3′, and a
forward mutagenic primer, 5′-TTCTGCAGACCCATG-
CAGATGCAAAAGACCAAGTGCTG-3′ (the mutated
codon is underlined). The wild-type sequences pGEX-
PrD5a WT and pCMV-PAX6-5a WT were replaced with
the PstI-NheI fragment derived from the PCR products,
generating pGEX-PrD5a V54D and pCMV-PAX6-5a
V54D. Mutated sequences were verified by sequencing
in the final constructs.
Gel-Shift Assays
In Escherichia coli cells of strain DH5a, a portion
of the PAX6 paired domain was produced as a fused
form with glutathione S-transferase (GST), by use of
pGEX-PrD WT and pGEX-PrD5a WT, and it was pu-
rified with a glutathione Sepharose column, according
to the manufacturer’s instructions (Amersham Phar-
macia). Oligonucleotides containing the consensus
binding sequences P6CON (5′-GGAATTCAGGAAAA-
ATTTTCACGCTTGAGTTCACAGCTCGAGT-3 ′)
and 5aCON (5′-AAATCTGAACATGCTCAGTGAAT-
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Figure 1 Photographs of the anterior segments (a and b) and the fundus of the right eye (c) of patient 1. In the left eye, the cornea is
opacified, and the cornea and iris adhere at the central portion (b). In the right eye of patient 1, the corneoscleral limbus is obscure (a), and
the foveal reflex is absent, with a residue of slight luteal pigment, and the blood vessels of the retina are not far from the presumed foveal
region (c). Patient 1’s mother had microphthalmos, cloudy corneoscleral limbus, aphakia after cataract surgery (d), and foveal hypoplasia (e).
Photographs of the anterior segments (f) and the fundus (g) of patient 2 show an obscure corneoscleral limbus and iridocorneal adhesion
(posterior embryotoxon) in the periphery. In the fundus of patient 2, the foveal reflex is absent, with a residue of slight luteal pigment, and the
blood vessels of the retina are not far from the presumed foveal region. Patient 3 shows microcornea and Peters anomaly (h) and retinal
degeneration (i). The right eye of patient 4 shows microcornea and congenital cataract (j).
GTTCATTGACTCTCGAGGTC-3′) were synthesized
(Epstein et al. 1994a, 1994b). Gel-shift assays were
performed as described elsewhere (Yamaguchi et al.
1997). In brief, an indicated amount of GST-PrD pro-
tein was incubated with the oligonucleotide in 10 ml
reaction buffer containing 50 mM Tris (pH 7.9), 20%
glycerol, 50 mM KCl, 0.1 mM EDTA, 5 mg BSA, and
1 mg poly dIdC for 30 min at 37oC and was then
subjected to electrophoresis through a 4% native poly-
acrylamide gel, with 0.5 # Tris-borate EDTA used as
running buffer.
Transfection and Luciferase Assays
Mouse embryonal carcinoma P19 cells were main-
tained in MEM medium (Gibco) supplemented with
10% fetal bovine serum at 37oC and a humidified at-
mosphere of 5% CO2. Reporter plasmids P6CON-luc
and 5aCON-luc, in which either six copies of P6CON
or two copies of 5aCON were situated upstream of the
adenovirus E4 minimal promoter, directed expression of
the luciferase gene, as described elsewhere (Yamaguchi
et al. 1997). A total of 5 # 104 P19 cells were plated
on 60-mm dishes, cultured for 20 h, and transfected with
a total of 10 mg DNA (5 mg of either P6CON-luc or
5aCON-luc, a various amount of pCMV-PAX6 or its
derivatives, and an empty vector, pCAGGS) by use of a
standard calcium phosphate method (Ausubel et al.
1995). Cells were harvested 42 h post transfection, and
luciferase activities were measured with cell lysates. The
luciferase activity was expressed as fold activation, with
the mean of three or five independent experiments, after
normalization with protein concentrations.
Results
Clinical Reports of Patients with the PAX6 Missense
Mutation
Patient 1, a 3-year-old girl, showed nystagmus, exo-
tropia, corneal opacity with iridocorneal adhesion (Pe-
ters anomaly) in the left eye, and corneal opacity with
sclerocornea and posterior embryotoxon in the right eye.
The fundus of the left eye could not be seen because of
a cloudy cornea, but the right eye showed foveal hy-
poplasia (fig. 1a–c ). At 8 years of age, the patient’s visual
acuity was 0.6 in the right eye, and her left eye could
detect hand movement only. Electroencephalography re-
sults were normal bilaterally, but echography findings
showed microphthalmos of the left eye (eyeball size, 21
mm). Her 36-year-old mother, who had undergone sur-
gery for bilateral congenital cataracts at the age of 14
years, had nystagmus, bilateral microphthalmos (eyeball
size, 22 mm), and foveal hypoplasia (fig. 1d and e). The
patient’s 37-year-old father had no ocular abnormalities.
Patient 2, a 16-year-old girl, showed nystagmus, slight
microcornea (corneal diameter, 10 mm), peripheral iri-
docorneal adhesion (Axenfeldt anomaly), and foveal hy-
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Figure 2 A, Band shift of SSCP, indicating that a heterozygous mutation was detected in the exon 5a region of patient 1 and her mother
but that it was not seen in their unaffected family members or in 1100 normal controls. B, Sequencing of the normal and mutant alleles, which
identified, at the 20th nucleotide of exon 5a, a heterozygous TrA transversion resulting in a ValrAsp substitution in the protein. The same
mutation was also identified in patients 2–4.
poplasia in both eyes (fig. 1f and g). Her visual acuity
was 0.1 bilaterally. Her electroencephalography results
were normal.
Patient 3, a 43-year-old woman, had undergone iri-
dectomy in both eyes after congenital corneal opacity
and cataract were diagnosed in childhood. She had bi-
lateral microcornea (corneal diameter, 8.5 mm), central
corneal opacity with iridocorneal adhesion (Peters
anomaly), cataract, posterior staphyloma with high my-
opia, and nystagmus (fig. 1h and i). Her vision was 0.04
in the right eye and 0.01 in the left eye, and her elec-
troencephalography results were subnormal bilaterally.
Computed-tomography and radiology findings showed
adhesion of cervical bones 1 and 2 plus a vascular anom-
aly in the brain stem.
Patient 4, a 3-mo-old female infant, had nystagmus
and bilateral congenital cataract (fig. 1j) and underwent
cataract surgery at 4 mo. Ophthalmoscopy and electro-
encephalography results were normal bilaterally; how-
ever, echography results showed microphthalmos (eye-
ball size, 20 mm). At 6 years of age, her visual acuity
with contact lenses was 0.6 bilaterally.
Computed-tomography results showed brain abnor-
mality in patient 3 only. All affected patients otherwise
had normal growth and intelligence, and their karyo-
types were normal.
Missense Mutation in the PAX6 Alternatively Spliced
Region
Using genomic DNA, we amplified 14 exons by PCR
and subjected the PCR products to SSCP analyses. An
abnormal pattern indicating a heterozygous mutation
was detected in the exon 5a region in patients 1–4 and
in the mother of patient 1 but was not detected in the
unaffected family members or in 1100 normal controls
(fig. 2A). Sequencing analysis demonstrated that, in each
of the affected patients, one allele had, at the 20th nu-
cleotide position of exon 5a, a TrA transversion that
resulted in a ValrAsp (GTCrGAC) substitution at the
7th codon of the 14-amino-acid stretch inserted into the
NTS region by alternative splicing (fig. 2B). No other
changes in nucleotide sequences were detected in PCR
products from patients’ genomic DNA. The mutation in
patient 4 is sporadic, since neither of her parents had
the mutation. In contrast, the origin of the mutation in
other families could not be determined, since the unaf-
fected family members of patients 2 and 3 were not
available for examination. All four pedigrees are Japa-
nese and originated in and live in a particular geographic
area in and near Tokyo. However, it remains unknown
whether the mutations found in patients 1, 2, and 3 are
derived from a common ancestral origin.
Effect of the V54D Mutation on PAX6-5a DNA-Binding
Activity
To analyze how the detected mutation affects the reg-
ulatory role of the PAX gene, we first examined the
DNA-binding activity of the V54D mutant, by use of a
gel-shift assay. Short peptides containing either the wild-
type or the V54D-mutated paired domain, which were
expressed in E. coli as a GST-fused form, were purified
and then were incubated with a[32P]-labeled P6CON or
5aCON probe. In agreement with the results of previous
studies, the paired domain containing 14 additional
amino acid residues encoded by exon 5a (GST-PrD5a
WT) barely bound to P6CON (fig. 3A, lanes 11–15).
However, the similar peptide containing the mutation
(GST-PrD5a V54D) slightly enhanced the binding to
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Figure 3 DNA-binding activity of the PAX6-5a V54D mutant. The PAX6 paired-domain wild type (PrD WT; lanes 1–5, at 3, 10, 30,
100, and 300 ng genomic DNA), the paired domain containing exon 5a (PrD5a WT; lanes 11–15), and the paired domain containing exon 5a
with the V54D mutation (PrD5a V54D; lanes 6–10) were incubated with either an a[32P]-labeled P6CON probe (A) or 5aCON (B) probe.
PrD5a WT shows barely detectable levels of P6CON binding, but the V54D mutation increases the level of P6CON binding. 5aCON binding
is not affected by the mutation.
P6CON (fig. 3A, lanes 6–10), indicating that the V54D
mutation is somehow likely to neutralize the negative
effect of insertion of exon 5a. On the other hand, both
peptides bound to 5aCON at almost similar levels, in-
dicating that the mutation has no effect on the 5aCON
binding (fig. 3B, lanes 6–15). Thus, in this binding assay,
the V54D mutation seems to affect only the NTS
structure.
Effect of the V54D Mutation on PAX6-5a
Transcriptional Activation
We next examined the transactivation activity of the
V54D mutation by use of a luciferase assay of trans-
fected cells. Two reporter plasmids, P6CON-luc and
5aCON-luc, contained six copies of P6CON and two
copies of 5aCON, respectively, which were located up-
stream of the adenovirus E4 minimal promoter, to direct
expression of the luciferase gene (Yamaguchi et al.
1997). Increasing amounts (1–300 ng) of the expression
plasmid for either PAX6 WT or the V54D mutant were
cotransfected, with a constant amount (5 mg) of either
P6CON-luc or 5aCON-luc, into P19 cells, and then the
luciferase activities were measured. As shown in figure
4A, the V54D mutant, as well as PAX6-5a WT, failed
to stimulate transcription from P6CON, whereas PAX6
without exon 5a stimulated transcription ∼20-fold. This
result seems to be inconsistent with that seen on gel-shift
assay. However, since P6CON binding by the V54D mu-
tant is 100-fold weaker than that by PAX6 WT (fig.
4A), transactivation via P6CON by PAX6-5a V54D may
be too weak to be detected by this assay. On the other
hand, transactivation via 5aCON was primarily ob-
served with PAX6 with exon 5a, as demonstrated pre-
viously, and the V54D mutation reduced the transacti-
vation activity to almost half (fig. 4B). Since, as
demonstrated above, the V54D mutation slightly re-
gained NTS binding ability, this observation is consistent
with the hypothesis that the transactivation activity via
5aCON is negatively correlated with the DNA-binding
activity of the NTS.
Discussion
We have identified a novel missense mutation, a
ValrAsp substitution at the 7th codon of the PAX6 al-
ternative splice region, in the pedigrees of four patients
with various eye anomalies. It is well known that PAX6
mutations cause various phenotypes; even in a pedigree
with aniridia, individuals with the same mutation
showed phenotypes ranging from total absence of the
iris to the presence of a normal-shaped iris. With the
exception of the pedigree of patient 1, the patients’ ped-
igrees did not have apparent family history of eye dis-
ease; however, members with extremely mild or nearly
normal phenotypes may have been overlooked.
Splice variants (with or without exon 5a) of PAX6
show distinct DNA-binding and transactivation prop-
erties. This has led to the idea that the 14 amino acids
encoded by exon 5a function as a molecular switch
that determines the target genes and their activation
(Epstein et al. 1994b; Yamaguchi et al. 1997). Func-
tional analyses have shown that the V54D mutation
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Figure 4 Transactivation potential of the PAX6-5a V54D mu-
tant. A, Expression plasmid expressing PAX6 WT (lanes 2–7, at 1, 3,
10, 30, 100, and 300 ng genomic DNA), PAX6-5a WT (lanes 8–13),
and PAX6-5a V54D (lanes 14–19) was cotransfected, with 5 mg of
either P6CON-luciferase reporter plasmid, into mouse embryonal car-
cinoma P19 cells. Both PAX6-5a V54D and PAX6-5a WT failed to
stimulate transcription from P6CON, whereas PAX6 WT stimulated
transcription ∼20-fold. B, Transfection performed as in panel A, with
the exception that 5aCON-luciferase plasmid was used as the reporter.
Pax6-5a WT possesses higher stimulatory activity than does PAX6
WT. V54D mutation reduces the transactivation potential approxi-
mately twofold.
slightly increases the affinity of PAX6-5a for P6CON,
without affecting its ability to bind 5aCON (fig.
3A).The NTS of the paired domain is responsible for
P6CON binding, and insertion of exon 5a into the
NTS abolishes the DNA-binding activity of the NTS
(Epstein et al. 1994b; Yamaguchi et al. 1997). Since
the amino acids Val and Asp are significantly different
in terms of their electronic charge, the mutation may
affect the NTS structure and, thereby, partially restore
the P6CON binding. In contrast to the result of a gel-
shift assay, however, the mutation could not recover
the P6CON-mediated transactivation. Instead, the
mutation mildly reduced transactivation from the
5aCON.
Several lines of evidence suggest that NTS and CTS,
the two DNA-binding subdomains of the PAX6 paired
domain, can independently bind to their cognate sites
(Epstein et al. 1994b). Our previous analyses, how-
ever, have shown that the two subdomains negatively
regulate the transactivation potentials of each other
in vivo (Yamaguchi et al. 1997). For instance, the in-
sertion of 14 additional amino acids encoded by exon
5a abolishes the NTS function and markedly enhances
transactivation via the CTS and 5aCON. This finding
can be interpreted as follows: when the CTS binds
5aCON, the NTS also interacts with the flanking se-
quences nonspecifically; this interaction constrains the
structure of the NTS, to provide a reduced level of
transactivation. In all cases examined to date, the
transactivation potentials of one subdomain are in-
versely correlated with the DNA binding activity of
the other subdomain. In the present study, the V54D
mutation mildly increased P6CON-binding activity
and decreased transactivation via 5aCON, a result
that also fits with this model.
Normal eye development is highly susceptible to the
level of PAX6 expression: haploinsufficiency causes an-
iridia, and overexpression also causes developmental de-
fects of the eye (Fisher and Scambler 1994; Schedl et al.
1996). A recent biochemical assay has indicated that
truncation mutations in the proline-serine-threonine
transactivation region of PAX6 have threefold- to five-
fold-higher affinity for DNA-binding sites than does the
wild-type PAX6; the assay also indicated that the mu-
tations are dominant-negative mutations, rather than
loss-of-function mutations (Singh et al. 1998). There-
fore, it is not surprising to expect that the twofold
variation is responsible for the observed eye anomalies.
Another possibility is that the binding and transcription
assays do not accurately show the PAX6 protein defect
that is due to the mutation. We might have failed to
detect the full consequence of the mutation occurring in
vivo. With the use of different cis-elements or different
cells (e.g., in the presence of putative cell type–specific
cofactors for PAX6), the mutation may cause a more
potent effect on its function.
A missense mutation in the NTS was identified in in-
dividuals with Peters anomaly who had a phenotype
limited to the anterior segments. Another mutation in
the CTS was detected in a case of foveal hypoplasia, in
which only the neural retina is affected. Aniridia involves
the entire eye (Glaser et al. 1992; Hanson et al. 1994;
Martha et al. 1994; Azuma et al. 1996). Almost all mu-
tations detected in aniridia are hemizygous or lead to a
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premature termination; thus, both the NTS and the CTS
must be involved. We previously had proposed that the
NTS affects the anterior segments and that the CTS af-
fects the posterior areas (Azuma et al. 1996). However,
the patients described in the present study have defects
in the anterior segment, in addition to foveal hypoplasia.
Thus, the regulation of eye formation by the PAX6 gene
may be more complex or may involve unknown mech-
anisms; for instance, the inactive mutants may act in a
dominant-negative manner by competing with some
coactivators.
According to the expression pattern of PAX6, the gene
is repeatedly expressed in the development of various
eye tissues (Walther and Gruss 1991). Among patients
in the present study, the phenotype had a range of ex-
pression, manifesting from anterior to posterior seg-
ments of the eye; this finding indicates that there are
multiple functions of the alternative splice. The alter-
native splice may help to control the use and activity of
the NTS and the CTS at different stages and in different
tissues, according to circumstances and in association
with some cofactors. Intriguingly, such a splice variant
is found only in vertebrates (Walther and Gruss 1991;
Epstein et al. 1994b). Thus, acquisition of the splice
variant during evolution may contribute to the forma-
tion of a highly complex eye structure to obtain better
vision.
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